[Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
Twenty-two patients with newly diagnosed advanced prostatic cancer treated with once-monthly subcutaneous injection of a long acting depot preparation of a new luteinizing hormone-releasing hormone superagonist (ICI 118,630) with a minimum follow-up duration of 6 months are reported. The partial regression rate was 45.4% while 36.4% of the patients had stable disease and only 18.2% have progressed by P.O.N.CA.P. criteria. Patient acceptance was excellent and side effects occurring during treatment (hot flashes, gynecomastia, etc.) were minimal. The depot preparation of the LH-RH analogue was well tolerated and no side effects required dose modifications or removal from the study. Depot LH-RH analogue may become an alternative treatment for patients with advanced prostatic cancer if further clinical evolutions will confirm that the response rate with LH-RH analogue is comparable to the conventional endocrine therapies.
Grifoni
R
R
Pierangeli
T
T
D000368:Aged; D000369:Aged, 80 and over; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D017273:Goserelin; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D003692:Delayed-Action Preparations; D017273:Goserelin; D002064:Buserelin
Trattamento del carcinoma prostatico in fase avanzata con LH-RH analogo in forma depot (ICI 118630).